# 10x Genomics, Inc. – Consensus ‘buy’ rating and 26.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/10x-genomics-inc.consensus-buy-rating-and-26.2-upside-potential/4121127671
- Published: 2023-09-19T13:57:45+01:00
- Author: Charlotte Edwards

**10x Genomics, Inc.** with ticker code (TXG) have now 12 market analysts covering
the stock. The analyst consensus now points to a rating of ‘buy’. The range between
the high target price and low target price is between 75 and 30 calculating the 
mean target price we have $62.75. Now with the previous closing price of $49.73 
and the analysts are correct then we can expect a percentage increase in value of
26.2%. It’s also worth noting that there is a 50 day moving average of $53.58 and
the 200 day moving average is $49.67. The market cap for the company is 5.42B. The
stock price for the company is currently 46.19 USD

 The potential market cap would be $6,843,493,993 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of 4.93 and
a -11.2% return on assets.

10x Genomics, Inc. is a life science technology company. The Company’s integrated
platform solutions include instruments, consumables and software for analyzing biological
systems. Its Chromium platform includes its Chromium X Series, Chromium Connect 
and legacy Chromium Controller instruments, microfluidic chips and related consumables,
enables throughput analysis of individual biological components. Its Visium platform
enables researchers to understand the spatial positions of biological analytes within
tissues at high resolution. Its products include Chromium Single Cell Gene Expression,
Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling,
Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium
Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, Visium
Spatial Proteogenomics and Xenium In Situ Gene Expression. Its patent portfolio 
comprises over 1,750 issued patents and patent applications.

Share on: